1-溴-2-(甲氧基甲氧基)萘 | 146746-73-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-溴-2-(甲氧基甲氧基)萘
• 英文名称: 1-bromo-2-(methoxymethoxy)naphthalene
• CAS: 146746-73-8
• 化学式: C₁₂H₁₁BrO₂
• mdl: MFCD21370981
• 分子量: 267.122
• InChiKey: FTXGUWMACJWOEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  358.2±22.0 °C(Predicted)
• 密度：
  1.431±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-溴-2-(甲氧基甲氧基)萘 在 bis(triphenylphosphine)palladium(II)-chloride 2,6-二甲基吡啶 、 盐酸 、 正丁基锂 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 lithium chloride 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.5h， 生成 苯并[k]荧蒽
  参考文献：
  名称：

  An intramolecular arene-triflate coupling reaction for the regiospecific synthesis of substituted benzofluoranthenes

  摘要：

  An intramolecular triflate-arene coupling reaction mediated by bis(triphenylphosphine)palladium(II) chloride has been developed for the synthesis of each of the isomeric benzofluoranthenes. This reaction, which results in formation of a new five-membered ring, proceeds in highest yield when performed using 0.1 equiv of the palladium catalyst, 3 equiv of lithium chloride, and 1.2 equiv of 1,8-diazabicyclo[5.4.0]undec-7-ene in N,N-dimethylformamide at 140-degrees-C. The biaryl precursors needed for the coupling reaction can be prepared by [1,2-bis(diphenylphosphino)ethane]nickel(II) chloride catalyzed coupling of an aryl bromide with an [o-(methoxymethoxy)aryl]magnesium bromide (prepared by ortho-lithiation of an aryl methoxymethyl ether followed by transmetalation with magnesium bromide). Using this procedure benzo[a]fluoranthene, benzo[b]fluoranthene, benzo[j]fluoranthene, and benzo[k]fluoranthene were prepared in yields of 84%, 85%, 93%, and 64%, respectively. The reaction to prepare benzo[j]fluoranthene was regiospecific and afforded none of the six-membered ring product, perylene. The method was extended to the preparation of benzo[b]fluoranthene (BbF) derivatives with fluoro or methoxy groups on the benzo ring. The cyclization of compounds possessing a methoxy group on the same ring as the triflate required the addition of 0.4 equiv of triphenylphosphine to the reaction mixture. Strategies are reported for the regiospecific preparation of 4-, 5-, 6-, and 7-substituted benzo[b]fluoranthenes. Evidence is presented which suggests the intermediacy of radicals in the oxidative-addition of aryl triflates to the palladium catalyst.

  DOI：

  10.1021/jo00058a023
• 作为产物：
  描述：

  2-萘酚 在 溴 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 反应 4.83h， 生成 1-溴-2-(甲氧基甲氧基)萘
  参考文献：
  名称：

  Selective detection of Cys and GSH by using one fluorescent probe at two excitation wavelengths

  摘要：

  Selective detection of Cys and GSH by using one fluorescent probe with two different excitation wavelengths is developed based on a naphthyl-coumarin aldehyde probe. Mechanistic studies indicate that the distinctively different fluorescent responses of the probe toward Cys and GSH at the two excitation wavelengths are due to two different reaction pathways that generate different products. The probe has been used to detect Cys and GSH in HeLa cells by using two emission channels. (C) 2020 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2020.152462

文献信息

• HandaPhos: A General Ligand Enabling Sustainable ppm Levels of Palladium-Catalyzed Cross-Couplings in Water at Room Temperature
  作者：Sachin Handa、Martin P. Andersson、Fabrice Gallou、John Reilly、Bruce H. Lipshutz

  DOI：10.1002/anie.201510570

  日期：2016.4.11

  complexed in a 1:1 ratio with Pd(OAc)2, enables Pd‐catalyzed cross‐couplings to be run using ≤1000 ppm of this pre‐catalyst. Applications to Suzuki–Miyaura reactions involving highly funtionalized reaction partners are demonstrated, all run using environmentally benign nanoreactors in water at ambient temperatures. Comparisons with existing state‐of‐the‐art ligands and catalysts are discussed herein.

  新的单膦配体HandaPhos已被鉴定为，当与Pd（OAc）2以1：1的比例络合时，可使用≤1000ppm的这种预催化剂进行Pd催化的交叉偶联。展示了在涉及高度官能化反应伙伴的Suzuki–Miyaura反应中的应用，所有反应均使用环境友好的纳米反应器在环境温度下的水中进行。本文讨论了与现有最​​先进的配体和催化剂的比较。
• 新規化合物、該化合物を含有する光酸発生剤、及び該光酸発生剤を含有する感光性樹脂組成物
  申请人：国立大学法人 奈良先端科学技術大学院大学

  公开号：JP2018118935A

  公开（公告）日：2018-08-02

  【課題】酸発生量子収率の高い非イオン系光酸発生剤の提供。【解決手段】式（２）で表される化合物。（環Ａｒはベンゼン環、ナフタレン環、チオフェン環等；Ｒ１は脂肪族炭化水素等。Ｒ２及びＲ３夫々独立にＨ、芳香族残基等；Ｒ４はＨ又は脂肪族炭化水素；Ｘ１はＣＲ５、Ｎ、Ｏ、Ｓ、Ｆ又はＰ；Ｒ５はＨ、芳香族残基等；Ｘ２はＣＲ６、Ｎ、Ｏ、Ｓ、Ｆ又はＰ；Ｒ６はＨ、芳香族残基等；Ｙ１はＳ，Ｏ、Ｓｅ又はＣＲ７Ｒ８；Ｒ７及びＲ８はＨ又は脂肪族炭化水素）【選択図】なし

  提供高产量非离子型光酸发生剂的解决方案是由式（2）表示的化合物。（环Ar代表苯环、萘环、噻吩环等；R1代表脂族烃等。R2和R3各自独立地代表H、芳香族残基等；R4代表H或脂族烃；X1代表CR5、N、O、S、F或P；R5代表H、芳香族残基等；X2代表CR6、N、O、S、F或P；R6代表H、芳香族残基等；Y1代表S、O、Se或CR7R8；R7和R8代表H或脂族烃）【选择图】无
• Protease inhibitors
  申请人：——

  公开号：US20020049316A1

  公开（公告）日：2002-04-25

  The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.

  本发明提供了一种公式（I）的化合物，其抑制蛋白酶，包括卡特普辛K，以及这些化合物的药物组合物，以及治疗骨量过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿关节炎；帕吉特病；高钙血症或恶性肿瘤；以及代谢性骨病。
• Synthesis and Photochromism of Novel Pyridyl-Substituted Naphthopyrans
  作者：Orlando D. C. C. de Azevedo、Paul I. P. Elliott、Christopher D. Gabbutt、B. Mark Heron、Kyle J. Lord、Christopher Pullen

  DOI：10.1021/acs.joc.0c01296

  日期：2020.8.21

  Multitarget synthetic strategies to access novel photochromic 3H-naphtho[2,1-b]pyrans decorated with pyridyl units are described. The new pyridyl-substituted 3H-naphtho[2,1-b]pyrans display good photochromic properties with reversible generation of photomerocyanines, which exhibit mainly orange/red hues. Photochromic parameters including photocolorability and persistence of color vary tremendously

  描述了多目标合成策略，以访问新型的吡啶基单元修饰的光致变色3 H-萘[ 2,1- b ]吡喃。新的吡啶基取代的3 H-萘[ 2,1 - b ]吡喃具有良好的光致变色特性，可逆生成的光金属花青素主要表现为橙色/红色。光致变色参数（包括光致变色性和颜色的持久性）在萘并吡喃核的结构修饰上有很大差异。
• [EN] KRAS G12C INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12C
  申请人：MIRATI THERAPEUTICS INC

  公开号：WO2020146613A1

  公开（公告）日：2020-07-16

  The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12C的化合物。特别是，本发明涉及不可逆地抑制KRas G12C活性的化合物，包括含有这些化合物的药物组合物及其用途方法。